Table 5.
Comparison of participants who were still on treatment or transferred out (n = 12,873) compared to those included in the final outcomes analysis (n = 170,017)
| Characteristics | Excludeda N = 12873 |
Included N = 170017 |
|
|---|---|---|---|
| Age at start of treatment (years) | <10 (children) | 875 (6.80%) | 17384 (10.22%) |
| 10–14 (young adolescents) | 120 (0.93%) | 1912 (1.12%) | |
| 15–19 (older adolescents) | 250 (1.94%) | 3681 (2.17%) | |
| 20–24 (young adults) | 945 (7.34%) | 10741 (6.32%) | |
| 25–49 (adults) | 9226 (71.67%) | 114137 (67.13%) | |
| ≥50 (older adults) | 1457 (11.32%) | 22162 (13.04%) | |
| District in Gauteng | Ekurhuleni Metropolitan Municipality | 4385 (34.06%) | 59919 (35.24%) |
| City of Johannesburg | 8488 (65.94%) | 110098 (64.76%) | |
| Registration year | 2010 | 3223 (25.04%) | 29481 (17.34%) |
| 2011 | 2301 (16.29%) | 29698 (17.47%) | |
| 2012 | 2097 (16.29%) | 28747 (16.91%) | |
| 2013 | 2094 (16.27%) | 28778 (16.93%) | |
| 2014 | 1845 (14.33%) | 27661 (16.27%) | |
| 2015 | 1313 (10.20%) | 25652 (15.09%) | |
| Sex | Female | 5953 (46.24%) | 76388 (44.93%) |
| Case definitionb | Bacteriologically confirmed | 8720 (67.74%) | 117640 (69.19%) |
| Clinically diagnosed | 2110 (16.39%) | 27548 (16.20%) | |
| Missing/Unknown | 2043 (15.87%) | 24829 (14.60%) | |
| Full case definition | Xpert MTB/RIF | 1400 (10.88%) | 27082 (15.93%) |
| Smear microscopy | 6377 (49.54%) | 80815 (47.53%) | |
| Culture | 429 (3.33%) | 5209 (3.06%) | |
| Aspiration/biopsy | 389 (3.02%) | 3534 (2.08%) | |
| CSF | 125 (0.97%) | 1000 (0.59%) | |
| X-ray | 1848 (14.36%) | 21872 (12.86%) | |
| Skin Test | 262 (2.04%) | 5676 (3.34%) | |
| Unknown clinical diagnosis | 2043 (15.87%) | 24829 (14.60%) | |
| Patient category | New Patient | 11740 (91.20%) | 160512 (94.41%) |
| Previously treated | 792 | 6667 | |
| Relapse | 534 (4.15%) | 4693 (2.76%) | |
| Re-treatment after failure | 91 (0.71%) | 719 (0.42%) | |
| Re-treatment after LTFU (default) | 167 (1.30%) | 1255 (0.74%) | |
| Unknown previous TB treatment history | 341 (2.65%) | 2838 (1.67%) | |
| Classification of Disease | Pulmonary TB | 9877 (76.73%) | 142843 (84.02%) |
| EPTB | 2996 (23.27%) | 27174 (15.98%) | |
| Smear status at initiation | Positive | 4298 (33.39%) | 63984 (37.63%) |
| Negative | 3261 (25.33%) | 40547 (23.85%) | |
| Missing | 5314 (41.28%) | 65486 (38.52%) | |
| HIV status | Positive, on ART | 4550 (35.35%) | 66871 (39.33%) |
| Positive, not on ART | 2608 (20.26%) | 27149 (15.97%) | |
| Positive, ART status unknown | 1565 (12.16%) | 15583 (9.17%) | |
| Negative | 2092 (16.25%) | 38692 (22.76%) | |
| HIV status unknown | 2058 (15.99%) | 21722 (12.78%) | |
| CD4 count (cells/mm3) if HIV positivec | ≤100 | 2170 (16.86%) | 23843 (14.02%) |
| 101–250 | 1539 (11.96%) | 18895 (11.11%) | |
| 251–350 | 441 (3.43%) | 6244 (3.67%) | |
| 351–500 | 326 (2.53%) | 4551 (2.68%) | |
| >500 | 213 (1.65%) | 3091 (1.82%) | |
| Missing | 8184 (63.57%) | 113433 (66.70%) | |
| Median (IQR) | 126 (52–250) | 113 (45–221) | |
| Started on cotrimoxazole prophylaxis | Yes | 6570 (75.32%) | 86984 (79.36%) |
| No | 1237 (14.18%) | 13535 (12.35%) | |
| Missing/unknown | 916 (10.50%) | 9084 (8.29%) | |
| Treatment regimen | Regimen 1 (2 RHZE/4 RH) | 11032 (85.70%) | 146174 (85.98%) |
| Regimen 2 (2 RHZES/1 HRZE/5 HRE) | 1063 (8.26%) | 8301 (4.88%) | |
| Regimen 3B (2 RHZE / 4 RH) | 778 (6.04%) | 15534 (9.14%) | |
| Other | 0 (0.00%) | 8 (0.00%) | |
| Treatment supervision (Intensive Phase) | Yes | 2356 (18.30%) | 26814 (15.77%) |
| No | 9205 (71.51%) | 119911 (70.53%) | |
| Missing | 1312 (10.19%) | 23292 (13.70%) | |
| Treatment supervision (Continuation Phase) | Yes | 414 (3.22%) | 7308 (4.30%) |
| No | 11147 (86.59%) | 139417 (82.00%) | |
| Missing | 1312 (10.19%) | 23292 (13.70%) | |
| Smear conversion at 2 monthsd | Yes | 185 (14.39%) | 22291 (70.88%) |
| No | 1101 (85.61%) | 9160 (29.12%) | |
| NA (Not smear positive at baseline or < 2 available smears) | 8176 | 97894 | |
| Any smear conversione | Yes | 672 (36.60%) | 55956 (95.06%) |
| No | 1164 (63.40%) | 2905 (4.94%) | |
| NA (Not smear positive at baseline or < 2 available smears) | 8176 | 97894 | |
Xpert MTB/RIF GeneXpert MTB/RIF, CSF cerebral spinal fluid, EPTB extra-pulmonary tuberculosis, LTFU loss to follow-up, HIV human immunodeficiency virus, ART antiretroviral therapy, IQR interquartile range
aExcluded cases include those who were still on treatment at ten months, those who were lost to follow-up, and those with unknown outcomes
bBacteriologically confirmed includes Xpert MTB/RIF, smear, or culture (and if aspiration/biopsy or cerebral spinal fluid (CSF) was listed, although the corresponding laboratory method was unknown). Clinically diagnosed includes X-ray and tuberculin skin test
cReported for HIV positive patients only
dSmear conversion at two months is two consecutive negative smears at least 30 days apart within two months of treatment initiation. One smear is sent monthly for smear microscopy
eAny smear conversion is two consecutive negative smears at least 30 days apart at any time after treatment initiation. Ascertained at the end of treatment